期刊文献+

卡巴他赛一种手性异构体杂质的合成

Synthesis of Chiral Isomer Impurity in Cabazitaxel
下载PDF
导出
摘要 本文介绍了卡巴他赛原料药的一种手性异构体杂质(2α,5β,7β,10β,13α)-4-乙酰氧基-2-苯甲酰氧基-5,20-环氧基-1-羟基-7,10-二甲氧基-9-氧代-11-紫杉烯-13-基-(2R,3R)-3-叔丁氧基羰基氨基-2-羟基-3-苯基丙酸酯的丙酮化合物的合成,该合成路线原料易得,反应条件温和,选择性高,操作简单。该异构体HPLC纯度超过98%,其结构得到NMR、MS确证,可以作为卡巴他赛原料药的质量控制的杂质对照品。 This report maily paied attention on the synthesis of one chiral isomer impurity of Cabazitaxel: (2ct, 513, 713, 1013, 13α)-4-acetoxy-13-({(2R,3R)-3-[(tertbutoxycarbonyl)amino]-2-hydroxy-3-phenylpropanpyl}oxy)-1-hydroxy-7,-dimethoxy-9-oxo-5,20-epoxytax-11-en-2-yl benzoate-propan-2-one(1 : 1). The materials are easy to get, the condition is modest, the selectivity is high and the operation is simple. The structures of target compounds were confirmed by NMR and MS, and their purities were higher than 98 % (by HPLC). These compounds can be used as the reference substances of the impurities in the quality control of Cabazitaxel.
作者 殷晓伟 康琳
出处 《广东化工》 CAS 2018年第1期59-60,共2页 Guangdong Chemical Industry
关键词 卡巴他赛 手性异构体杂质 合成 质量控制 Cabazitaxel chiral isomer impurities synthesis quality control
  • 相关文献

参考文献3

二级参考文献21

  • 1邵常霞,项永兵,刘振伟,高静,孙璐,方茹蓉,阮志贤,高立峰,金凡,高玉堂.上海市区泌尿系统恶性肿瘤相对生存率分析[J].中国肿瘤临床,2005,32(6):321-324. 被引量:31
  • 2叶定伟.前列腺癌的流行病学和中国的发病趋势[J].中华外科杂志,2006,44(6):362-364. 被引量:168
  • 3JEMAL A, SIEGEL R, WARD E, et al. Cancer statistics, 2009 [J]. CA Cancer JClin, 2009, 59(4): 225 -249.
  • 4PETRYLAK DP, TANGEN CM, HUSSAIN MH, et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer [ J ]. N Engl J Med, 2004, 351(15) : 1513 -1520.
  • 5BERRY DL, MOINPOUR CM, JIANG CS, et al. Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone[ J]. J Clin Oncol, 2006, 24(18) : 2828 -2835.
  • 6Jevtana [ EB/OL ].[ 2010 - 11 - 02 ]. http ://www. accessdata. fda. gov/drugsatfda_docs/label/2010/2010231bl, pdf.
  • 7Sanofi-aventis. XRP6258 investigator's brochure[ M]. Antony (France) : Sanofi-aventis,2000.
  • 8ATTARD G, GREYSTOKE A, KAYE S, et al. Update on tubulin binding agents [ J ]. Pathol Biol( Paris), 2006, 54 ( 2 ) : 72 - 84.
  • 9PIVOTI X, KORALEWSKI P, HIDALGO JL, et al. A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients [J]. Ann Oncol, 2008, 19(9) : 1547 -1552.
  • 10SEBASTIAN J, OUDARD S, OZGUROGLU M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic astration-resistant prostate cancer progressing after ocetaxel treatment: a randomised open-label trial [ J ]. Lancet, 2010, 376 ( 9747 ) : 1147 - 1154.

共引文献136

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部